Kurlan R, Kim M H, Gash D M
Department of Neurology, University of Rochester School of Medicine, NY 14642.
Mov Disord. 1991;6(2):111-8. doi: 10.1002/mds.870060205.
Quantitative measures for the severity of MPTP-induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose-response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose-response relationship for levodopa over the dosage range of 50-3,500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000-2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP-induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.
一直缺乏针对MPTP诱导的帕金森症严重程度以及猴子对抗帕金森干预反应的定量测量方法。我们对两只通过颈内注射MPTP诱导出左侧偏侧帕金森症的恒河猴进行了口服左旋多巴剂量反应研究。一种新开发的猴子帕金森症临床评分量表显示，在50 - 3500毫克/天的剂量范围内，左旋多巴呈现出一致的剂量反应关系。抗帕金森作用在200毫克/天出现，在1000 - 2000毫克/天达到最佳效果。左旋多巴还能逆转旋转行为，改善受损上肢和对侧上肢的运动时间，并在高剂量时产生运动障碍。因此，MPTP诱导的猴子偏侧帕金森症与人类疾病状况非常相似，具有敏感的反应测量指标，并且对于评估新型抗帕金森疗法应具有重要价值。
